Peptide Graded

Somapacitan

Is Somapacitan safe?

Trial and label safety data

AStrong human evidenceFDA approvedas of 2026-10-26

Side effects match those of growth hormone in general. They include headache, joint and muscle pain, and swelling from fluid retention. Adults may get carpal tunnel symptoms. These came mostly early in treatment and depended on the dose. Injection site reactions were mild. Growth hormone raises blood glucose and can unmask diabetes, so doctors monitor glucose. The label carries the class warnings. People with active cancer or acute critical illness should not use it. Children with Prader-Willi syndrome who are severely obese or have severe breathing problems should not use it. Doctors should watch for slipped hip growth plates and worsening scoliosis in growing children. Anti-drug antibodies were rare and did not neutralize the hormone. Daily growth hormone has a four-decade safety record in children, and long-term pediatric safety follows it. But weekly dosing produces higher peak IGF-1 than daily dosing. Whether that matters over decades is not yet known. 12

Read the full Somapacitan page

More on Somapacitan

Citations

  1. Johannsson 2020, J Clin Endocrinol Metab: once-weekly somapacitan vs daily GH in adults with GH deficiency (REAL 1) pubmed.ncbi.nlm.nih.gov
  2. Sogroya (somapacitan-beco) prescribing information, Novo Nordisk novo-pi.com
  3. HCPLive, Feb 2026: FDA approves three new pediatric indications for somapacitan (REAL8) hcplive.com

Reference information only, not medical advice. Drawn from the Somapacitan article, fact-checked against the cited sources. No dosing anywhere on this site.